Williamson Legacy Group LLC Sells 3,473 Shares of Insulet Corporation $PODD

Williamson Legacy Group LLC lowered its position in Insulet Corporation (NASDAQ:PODD) by 74.4% during the 4th quarter, Holdings Channel reports. The firm owned 1,196 shares of the medical instruments supplier’s stock after selling 3,473 shares during the quarter. Williamson Legacy Group LLC’s holdings in Insulet were worth $340,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of PODD. Larson Financial Group LLC grew its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter. Elyxium Wealth LLC bought a new position in Insulet in the fourth quarter worth approximately $28,000. Whittier Trust Co. of Nevada Inc. grew its stake in Insulet by 48.9% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new position in Insulet in the third quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. bought a new position in Insulet in the second quarter worth approximately $51,000.

Insulet Stock Down 0.7%

Insulet stock opened at $153.80 on Wednesday. The business has a fifty day moving average of $188.59 and a two-hundred day moving average of $248.51. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a market cap of $10.65 billion, a P/E ratio of 35.77, a P/E/G ratio of 1.23 and a beta of 1.20. Insulet Corporation has a twelve month low of $145.59 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same quarter in the prior year, the business posted $1.02 EPS. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts forecast that Insulet Corporation will post 6.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on PODD. Wall Street Zen upgraded Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Leerink Partners lowered their target price on Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Stifel Nicolaus lowered their target price on Insulet from $350.00 to $250.00 in a report on Thursday, May 7th. Benchmark began coverage on Insulet in a report on Tuesday, May 12th. They set a “buy” rating for the company. Finally, Sanford C. Bernstein lowered their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average target price of $253.87.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.